As a cure for pulmonary alveolar proteinosis (PAP) has not been found yet and patients respond differently or sometimes not at all to the existing treatments, the search for new effective therapies is a continuous process.
Currently, researchers are conducting clinical trials looking into the effect and safety of immune-modulating treatment (GM-CSF) or immune-suppressive treatment for autoimmune PAP.
A clinical trial is a research study involving human volunteers. The intention is to add to medical knowledge about a drug, a device, or other forms of treatment. Clinical trials are the fastest and safest way to find treatments that work in people and methods to improve health. Interventional trials determine whether experimental treatments or new ways of using known therapies are safe and effective under controlled environments.
All clinical trials have guidelines about who can participate. Thus, not all patients may be eligible to participate in a clinical trial. Researchers use inclusion criteria and exclusion criteria to determine which patients are eligible. How the criteria are set depends on the purpose of the trial. The guidelines for each trial has been approved by regulatory authorities and research ethics committees to ensure safety of the participants and the appropriateness of the trial protocol to show if the treatment is effective or not.